Jupiter Neurosciences Inc (JUNS) Smart Money Holdings (13F, Q2 2026)

AI summary pending

No AI summary for this filing type

AI summary pending

On August 21, 2026, Jupiter Neurosciences (JUNS) lined up fresh cash from two sources: a registered direct offering of about 307,700 shares at $6.50 apiece for roughly $2.0 million gross — with D. Boral Capital as placement agent taking a 7% fee, expected to close around August 24 — and the sale of about 107,900 shares for approximately $851,000 to Yorkville between August 14 and 21 under the company's pre-existing standby equity purchase agreement, priced at 97% of the stock's volume-weighted average price during each pricing period. The company also agreed to hold off on issuing or selling any more stock for 30 days after the offering closes.

Jupiter Neurosciences (JUNS) closed a small registered direct offering on August 24, 2026, selling 307,692 shares of common stock at $6.50 per share for gross proceeds of about $2.0 million before fees. The company says this should lift its stockholders' equity above the $2.5 million minimum Nasdaq requires for continued listing on the Capital Market, though it's still awaiting Nasdaq's formal confirmation of compliance. The filing also notes the stock could face delisting if equity falls short again by the time of its next periodic report.

AI summary pending

Jupiter Neurosciences disclosed in an 8-K filing that between May 14 and July 24, 2026, it sold 11.47 million shares of common stock to Yorkville under an existing Standby Equity Purchase Agreement (SEPA), generating gross proceeds of about $3.6 million. The shares were priced at 97% of the lowest daily volume-weighted average price (VWAP) over a three-day pricing period, and the sales relied on an exemption from registration.

Jupiter Neurosciences (JUNS) held its 2026 Annual Meeting on July 22, 2026. All seven director nominees were elected with strong support, and the appointment of Cherry Bekaert as auditor was ratified. On the advisory "say-on-pay" vote for executive compensation, while a majority voted in favor, roughly 2.4 million shares voted against and about 9.4 million broker non-votes were recorded, suggesting some shareholder unease. Another vote on the frequency of future say-on-pay proposals was also held, but the filing does not specify which frequency option won, leaving the outcome unclear.

Jupiter Neurosciences signed a definitive license agreement with PharmAla Biotech to develop and sell PharmAla's drug ALA-002 in the United States. Jupiter will pay $3.33 million upfront—part cash, part stock—and up to $96.67 million in milestone payments plus royalties if the drug succeeds. The deal covers all human therapeutic uses in the U.S.

Jupiter Neurosciences appointed Dr. Tomas J. Philipson to its board, effective June 26, 2026. He also joined the Audit and Compensation Committees. Dr. Philipson is an economist with experience in academia, government (including serving as Acting Chairman of the White House Council of Economic Advisers), and the private sector. He will receive stock options in lieu of cash compensation, including a sign-on option for 90,000 shares and annual equity grants for 446,428 shares.